Was this medicine useful for you?
What is Levofloxacina Eurogenerici?
Levofloxacina Eurogenerici injection is used to treat bacterial infections in many different parts of the body. It is also used to prevent an anthrax infection after a person has been exposed to anthrax. Levofloxacina Eurogenerici is also used to treat and prevent plague (including pneumonic and septicemic plague).
Levofloxacina Eurogenerici belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. However, Levofloxacina Eurogenerici will not work for colds, flu, or other virus infections.
Levofloxacina Eurogenerici is to be given only by or under the direct supervision of your doctor.
Levofloxacina Eurogenerici indications
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Levofloxacina Eurogenerici and other antibacterial drugs, Levofloxacina Eurogenerici should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Oral Solution are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section.
Culture and susceptibility testing
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to Levofloxacina Eurogenerici. Therapy with Levofloxacina Eurogenerici may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.
As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Levofloxacina Eurogenerici. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.
Levofloxacina Eurogenerici is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended.
Community-Acquired Pneumonia: 7–14 day Treatment Regimen
Levofloxacina Eurogenerici is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae.
MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
Community-Acquired Pneumonia: 5-day Treatment Regimen
Levofloxacina Eurogenerici is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae.
Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens
Levofloxacina Eurogenerici is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.
Acute Bacterial Exacerbation of Chronic Bronchitis
Levofloxacina Eurogenerici is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.
Complicated Skin and Skin Structure Infections
Levofloxacina Eurogenerici is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis.
Uncomplicated Skin and Skin Structure Infections
Levofloxacina Eurogenerici is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes.
Chronic Bacterial Prostatitis
Levofloxacina Eurogenerici is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis.
Complicated Urinary Tract Infections: 5-day Treatment Regimen
Levofloxacina Eurogenerici is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.
Complicated Urinary Tract Infections: 10-day Treatment Regimen
Levofloxacina Eurogenerici is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa.
Acute Pyelonephritis: 5 or 10-day Treatment Regimen
Levofloxacina Eurogenerici is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia.
Uncomplicated Urinary Tract Infections
Levofloxacina Eurogenerici is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus.
Inhalational Anthrax (Post-Exposure)
Levofloxacina Eurogenerici is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of Levofloxacina Eurogenerici is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacina Eurogenerici has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of Levofloxacina Eurogenerici in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged Levofloxacina Eurogenerici therapy should only be used when the benefit outweighs the risk.
Levofloxacina Eurogenerici is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of Levofloxacina Eurogenerici could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals.
How should I use Levofloxacina Eurogenerici?
Use Levofloxacina Eurogenerici as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Levofloxacina Eurogenerici comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Levofloxacina Eurogenerici refilled.
- Take Levofloxacina Eurogenerici by mouth on an empty stomach at least 1 hour before or 2 hours after eating.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- Drinking extra fluids while you are taking Levofloxacina Eurogenerici is recommended. Check with your doctor for instructions.
- Do not take a product that has magnesium, aluminum, calcium, zinc, or iron in it within 2 hours before or 2 hours after you take Levofloxacina Eurogenerici. Examples of these products include certain antacids, multivitamins, quinapril, and calcium-fortified orange juice. Check with your doctor or pharmacist if you have a question about whether you should separate Levofloxacina Eurogenerici from a certain food or product.
- If you also take sucralfate or didanosine, do not take them within 2 hours before or 2 hours after taking Levofloxacina Eurogenerici. Check with your doctor if you have questions.
- Levofloxacina Eurogenerici works best if it is taken at the same time each day.
- To clear up your infection completely, take Levofloxacina Eurogenerici for the full course of treatment. Keep taking it even if you feel better in a few days.
- Do not miss any doses of Levofloxacina Eurogenerici. If you miss a dose of Levofloxacina Eurogenerici, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once or more than 1 dose in 1 day.
Ask your health care provider any questions you may have about how to use Levofloxacina Eurogenerici.
Uses of Levofloxacina Eurogenerici in details
Levofloxacina Eurogenerici is used to treat bacterial infections of the respiratory tract, urinary tract, ear, tooth and prostate gland. It is also used to treat skin and soft tissue infections, anthrax and plague.
Levofloxacina Eurogenerici description
Each tablet contains Levofloxacina Eurogenerici 250 mg as active ingredient corresponding to Levofloxacina Eurogenerici hemihydrate 256.23 mg.
Levofloxacina Eurogenerici also contains the following inactive ingredients: Sodium chloride; sodium hydroxide; hydrochloric acid (qs: pH 4.8) and water for injection for a volume of 100 mL (Na+ concentration: 154 mmol/L).
Levofloxacina Eurogenerici is a synthetic broad-spectrum antibacterial agent for oral and IV administration. Chemically, Levofloxacina Eurogenerici, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. Levofloxacina Eurogenerici is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate.
Its empirical formula is C18H20FN3O4·½H2O and its molecular weight is 370.38.
Levofloxacina Eurogenerici is a light yellowish-white to yellow-white crystal or crystalline powder. The molecule exists as a zwitterion at the pH conditions in the small intestine. The data demonstrate that from pH 0.6-5.8, the solubility of Levofloxacina Eurogenerici is essentially constant (approximately 100 mg/mL). Levofloxacina Eurogenerici is considered soluble to freely soluble in this pH range, as defined by USP nomenclature. Above pH 5.8, the solubility increases rapidly to its maximum at pH 6.7 (272 mg/mL) and is considered freely soluble in this range. Above pH 6.7, the solubility decreases and reaches a minimum value (about 50 mg/mL) at a pH of approximately 6.9. Levofloxacina Eurogenerici has the potential to form stable coordination compounds with many metal ions. This in vitro chelation potential has the following formation order: A1+3 > Cu+2 > Zn+2 > Mg+2 > Ca+2.
Levofloxacina Eurogenerici dosage
Dosage in Adult Patients with Normal Renal Function
The usual dose of Levofloxacina Eurogenerici Tablets, USP is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1.
These recommendations apply to patients with creatinine clearance ≥ 50 mL/min. For patients with creatinine clearance <50 mL/min, adjustments to the dosing regimen are required.
Dosage in Pediatric Patients
The dosage in pediatric patients ≥ 6 months of age is described below in Table 2.
Dosage Adjustment in Adults with Renal Impairment
Administer Levofloxacina Eurogenerici Tablets, USP with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of Levofloxacina Eurogenerici may be reduced.
No adjustment is necessary for patients with a creatinine clearance ≥ 50 mL/min.
In patients with impaired renal function (creatinine clearance <50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of Levofloxacina Eurogenerici due to decreased clearance.
Table 3 shows how to adjust dose based on creatinine clearance.
Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins
Levofloxacina Eurogenerici Tablets
Levofloxacina Eurogenerici Tablets, USP should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable/buffered tablets or the pediatric powder for oral solution.
Food and Levofloxacina Eurogenerici Tablets, USP
Levofloxacina Eurogenerici Tablets, USP can be administered without regard to food.
Hydration for Patients Receiving Levofloxacina Eurogenerici Tablets, USP
Adequate hydration of patients receiving oral Levofloxacina Eurogenerici Tablets, USP should be maintained to prevent the formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones.
Levofloxacina Eurogenerici interactions
There are no data concerning an interaction of quinolones IV with oral antacids, sucralfate, multivitamins, didanosine or metal cations. However, no quinolone should be co-administered with any solution containing multivalent cations eg, magnesium, through the same IV line.
Theophylline: No significant effect of Levofloxacina Eurogenerici on the plasma concentrations, AUC and other disposition parameters for theophylline was detected in a clinical study involving 14 healthy volunteers. Similarly, no apparent effect of theophylline on Levofloxacina Eurogenerici absorption and disposition was observed. However, concomitant administration of other quinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when Levofloxacina Eurogenerici is co-administered. Adverse reactions, including seizures, may occur with or without an elevation in serum theophylline levels.
Warfarin: No significant effect of Levofloxacina Eurogenerici on the Cmax, AUC and other disposition parameters for R- and S-warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on Levofloxacina Eurogenerici absorption and disposition was observed. There have been reports during the postmarketing experience in patients that Levofloxacina Eurogenerici enhances the effects of warfarin. Elevations of the prothrombin time in the setting of concurrent warfarin and Levofloxacina Eurogenerici use have been associated with episodes of bleeding. Prothrombin time, INR or other suitable anticoagulation tests should be closely monitored if Levofloxacina Eurogenerici is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding.
Cyclosporine: No significant effect of Levofloxacina Eurogenerici on the Cmax, AUC and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when co-administered with some other quinolones. Levofloxacina Eurogenerici Cmax and ke were slightly lower while Tmax and t½ were slightly longer in the presence of cyclosporine than those observed in other studies without concomitant medication. The differences, however, are not considered to be clinically significant. Therefore, no dosage adjustment is required for Levofloxacina Eurogenerici or cyclosporine when administered concomitantly.
Digoxin: No significant effect of Levofloxacina Eurogenerici on the Cmax, AUC and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacina Eurogenerici absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for Levofloxacina Eurogenerici or digoxin is required when administered concomitantly.
Probenecid and Cimetidine: No significant effect of probenecid or cimetidine on the rate and extent of Levofloxacina Eurogenerici absorption were observed in a clinical study involving healthy volunteers. The AUC and t1/2 of Levofloxacina Eurogenerici were 27-38% and 30% higher, respectively, while CL/F and CLR were 21-35% lower during concomitant treatment with probenecid or cimetidine compared to Levofloxacina Eurogenerici alone. Although these differences were statistically significant, the changes were not high enough to warrant dosage adjustment for Levofloxacina Eurogenerici when probenecid or cimetidine is co-administered.
Nonsteroidal Anti-Inflammatory Drugs: The concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone, including Levofloxacina Eurogenerici, may increase the risk of CNS stimulation and convulsive seizures.
Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered.
Levofloxacina Eurogenerici side effects
Serious and Otherwise Important Adverse Reactions
The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:
- Tendon Effects
- Exacerbation of Myasthenia Gravis
- Hypersensitivity Reactions
- Other Serious and Sometimes Fatal Reactions
- Central Nervous System Effects
- Clostridium difficile-Associated Diarrhea
- Peripheral Neuropathy that may be irreversible
- Prolongation of the QT Interval
- Musculoskeletal Disorders in Pediatric Patients
- Blood Glucose Disturbances
- Photosensitivity/Phototoxicity [see
- Development of Drug Resistant Bacteria
Hypotension has been associated with rapid or bolus intravenous infusion of Levofloxacina Eurogenerici. Levofloxacina Eurogenerici should be infused slowly over 60 to 90 minutes, depending on dosage.
Crystalluria and cylindruria have been reported with quinolones, including Levofloxacina Eurogenerici. Therefore, adequate hydration of patients receiving Levofloxacina Eurogenerici should be maintained to prevent the formation of a highly concentrated urine.
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Levofloxacina Eurogenerici in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was < 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with Levofloxacina Eurogenerici for a wide variety of infectious diseases. Patients received Levofloxacina Eurogenerici doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily. Treatment duration was usually 3 to 14 days, and the mean number of days on therapy was 10 days.
The overall incidence, type and distribution of adverse reactions was similar in patients receiving Levofloxacina Eurogenerici doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of Levofloxacina Eurogenerici due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose. The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily nausea (0.6%); vomiting (0.4%); dizziness (0.3%); and headache (0.2%). The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily nausea (0.6%), vomiting (0.5%); dizziness (0.3%); and headache (0.3%).
Adverse reactions occurring in ≥1% of levofloxacin-treated patients and less common adverse reactions, occurring in 0.1 to <1% of levofloxacin-treated patients, are shown in Table 6 and Table 7, respectively. The most common adverse drug reactions (≥3%) are nausea, headache, diarrhea, insomnia, constipation, and dizziness.
In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment with quinolones, including Levofloxacina Eurogenerici. The relationship of the drugs to these events is not presently established.
Table 8 lists adverse reactions that have been identified during post-approval use of Levofloxacina Eurogenerici. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.
Levofloxacina Eurogenerici contraindications
Patients hypersensitive to Levofloxacina Eurogenerici or any other quinolones or any excipients of Levofloxacina Eurogenerici. Patients with epilepsy and those with history of tendon disorder related to fluoroquinolone administration.
Use in pregnancy: Levofloxacina Eurogenerici caused no impairment of fertility or reproductive performance in rats at oral doses as high as 360 mg/kg/day. It was not teratogenic in rats at oral doses as high as 810 mg/kg/day or at IV dose up to 160 mg/kg/day. No teratogenicity was observed when rabbits were dosed orally as high as 50 mg/kg/day.
In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, Levofloxacina Eurogenerici must not be used in pregnant women or women suspected of being pregnant.
Use in lactation: In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, Levofloxacina Eurogenerici must not be used in breastfeeding women.
Use in children: Safety and effectiveness in pediatric patients and adolescents <16 years have not been established. Quinolones, including Levofloxacina Eurogenerici, cause arthropathy and osteochondrosis in juvenile animals of several species.
Elderly: The pharmacokinetic properties of Levofloxacina Eurogenerici in younger adults and elderly do not differ significantly when creatinine clearance is taken into consideration. However, since Levofloxacina Eurogenerici is known to be substantially excreted by the kidney, the risk of toxic reactions to Levofloxacina Eurogenerici may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.
Active ingredient matches for Levofloxacina Eurogenerici:
Levofloxacin in Italy.
- DailyMed. "LEVOFLOXACIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailymed/se... (accessed September 18, 2017).
- PubChem. "LEVOFLOXACIN". https://pubchem.ncbi.nlm.nih.gov/compoun... (accessed September 18, 2017).
ReviewsThe results of a survey conducted on ndrugs.com for Levofloxacina Eurogenerici are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Levofloxacina Eurogenerici. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet
Information checked by Dr. Sachin Kumar, MD Pharmacology